Akèy › Limfom Difize Gwo Selil B › Connecticut
Etid klinik pou Limfom Difize Gwo Selil B nan Connecticut
8 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan Connecticut.
Vil nan Connecticut
Tèks ofisyèl etid la (Anglè)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center - Guilford, Guilford
- Yale University, New Haven
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06649812A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Yale University School of Medicine - Yale Cancer Center, New Haven
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Yale New Haven Hospital ( Site 1012), New Haven
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
- Yale University, New Haven
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT05272384Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- Yale University, New Haven
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06116110DALY II USA/ MB-CART2019.1 for DLBCL
- Yale University, New Haven
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Yale Cancer Center, New Haven
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
- Yale University, New Haven
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT06898905Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.